| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 63 | 2023 | 2034 | 4.850 |
Why?
|
| Contrast Media | 38 | 2023 | 408 | 4.320 |
Why?
|
| Peroxidase | 12 | 2023 | 69 | 3.980 |
Why?
|
| Fluorescent Dyes | 19 | 2019 | 195 | 3.090 |
Why?
|
| Oligodeoxyribonucleotides | 9 | 2019 | 243 | 2.350 |
Why?
|
| Polyethylene Glycols | 17 | 2019 | 162 | 2.040 |
Why?
|
| Molecular Imaging | 7 | 2017 | 47 | 2.000 |
Why?
|
| Polylysine | 12 | 2019 | 49 | 1.650 |
Why?
|
| Nanoparticles | 4 | 2020 | 496 | 1.550 |
Why?
|
| Organometallic Compounds | 6 | 2022 | 64 | 1.550 |
Why?
|
| Intracranial Aneurysm | 5 | 2024 | 335 | 1.470 |
Why?
|
| NF-kappa B | 5 | 2019 | 461 | 1.460 |
Why?
|
| Carbocyanines | 11 | 2017 | 29 | 1.410 |
Why?
|
| Endothelium, Vascular | 7 | 2020 | 172 | 1.400 |
Why?
|
| Gadolinium DTPA | 19 | 2018 | 85 | 1.370 |
Why?
|
| Animals | 96 | 2023 | 19616 | 1.310 |
Why?
|
| ErbB Receptors | 4 | 2021 | 111 | 1.230 |
Why?
|
| Biosensing Techniques | 3 | 2019 | 114 | 1.200 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 72 | 1.070 |
Why?
|
| Drug Carriers | 8 | 2019 | 171 | 1.010 |
Why?
|
| Image Enhancement | 6 | 2014 | 190 | 1.010 |
Why?
|
| Aneurysm | 2 | 2020 | 53 | 1.000 |
Why?
|
| Enzymes | 3 | 2013 | 32 | 0.990 |
Why?
|
| Ferric Compounds | 9 | 2015 | 38 | 0.950 |
Why?
|
| Rats | 37 | 2021 | 1907 | 0.940 |
Why?
|
| Glioma | 4 | 2013 | 102 | 0.940 |
Why?
|
| Pentetic Acid | 11 | 2012 | 32 | 0.930 |
Why?
|
| Luminescent Proteins | 7 | 2022 | 129 | 0.920 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2020 | 292 | 0.870 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 195 | 0.870 |
Why?
|
| Oligonucleotides | 2 | 2020 | 208 | 0.860 |
Why?
|
| Mice | 50 | 2020 | 10259 | 0.850 |
Why?
|
| Fluorine | 2 | 2020 | 9 | 0.850 |
Why?
|
| Gold | 2 | 2015 | 227 | 0.840 |
Why?
|
| Image Processing, Computer-Assisted | 9 | 2020 | 636 | 0.830 |
Why?
|
| Fluorescence Resonance Energy Transfer | 6 | 2013 | 72 | 0.820 |
Why?
|
| Brain Neoplasms | 7 | 2013 | 306 | 0.810 |
Why?
|
| Optical Imaging | 2 | 2022 | 68 | 0.770 |
Why?
|
| Liposomes | 7 | 2014 | 98 | 0.770 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 2062 | 0.760 |
Why?
|
| Neoplasms | 6 | 2022 | 1234 | 0.750 |
Why?
|
| Molecular Probes | 3 | 2017 | 29 | 0.750 |
Why?
|
| Gadolinium | 7 | 2012 | 101 | 0.740 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 42 | 0.740 |
Why?
|
| Genes, Reporter | 6 | 2009 | 243 | 0.730 |
Why?
|
| HIV Infections | 2 | 2019 | 919 | 0.720 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 23 | 0.720 |
Why?
|
| NF-kappa B p50 Subunit | 3 | 2011 | 22 | 0.700 |
Why?
|
| Anti-HIV Agents | 2 | 2019 | 153 | 0.700 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2019 | 28 | 0.700 |
Why?
|
| Genetic Therapy | 9 | 2004 | 734 | 0.700 |
Why?
|
| Cell Line, Tumor | 11 | 2017 | 1370 | 0.690 |
Why?
|
| Dextrans | 6 | 2015 | 44 | 0.690 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 117 | 0.690 |
Why?
|
| DNA | 5 | 2011 | 793 | 0.690 |
Why?
|
| Antibodies, Monoclonal | 7 | 2013 | 870 | 0.690 |
Why?
|
| E-Selectin | 4 | 2006 | 19 | 0.680 |
Why?
|
| Rabbits | 10 | 2023 | 330 | 0.680 |
Why?
|
| Nucleic Acid Conformation | 3 | 2013 | 231 | 0.640 |
Why?
|
| Polymers | 6 | 2013 | 315 | 0.640 |
Why?
|
| Iron | 9 | 2023 | 144 | 0.640 |
Why?
|
| Fluorescence | 5 | 2013 | 84 | 0.640 |
Why?
|
| Endothelial Cells | 3 | 2009 | 177 | 0.630 |
Why?
|
| Cytoplasm | 2 | 2019 | 273 | 0.630 |
Why?
|
| Precision Medicine | 1 | 2020 | 102 | 0.630 |
Why?
|
| Monophenol Monooxygenase | 3 | 2007 | 6 | 0.620 |
Why?
|
| Humans | 69 | 2024 | 59329 | 0.620 |
Why?
|
| Early Diagnosis | 1 | 2019 | 89 | 0.620 |
Why?
|
| Peptide Hydrolases | 1 | 2019 | 78 | 0.610 |
Why?
|
| Neovascularization, Pathologic | 10 | 2005 | 138 | 0.600 |
Why?
|
| Transfection | 12 | 2006 | 673 | 0.600 |
Why?
|
| Islets of Langerhans | 1 | 2019 | 267 | 0.600 |
Why?
|
| Chelating Agents | 4 | 2012 | 47 | 0.590 |
Why?
|
| Tumor Cells, Cultured | 13 | 2002 | 454 | 0.580 |
Why?
|
| Technetium | 5 | 2003 | 68 | 0.580 |
Why?
|
| Intracellular Space | 1 | 2017 | 32 | 0.580 |
Why?
|
| Neoplasm Transplantation | 15 | 2013 | 158 | 0.570 |
Why?
|
| Fluorocarbons | 1 | 2017 | 32 | 0.570 |
Why?
|
| Metal Nanoparticles | 3 | 2015 | 180 | 0.560 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2014 | 180 | 0.560 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 68 | 0.550 |
Why?
|
| Diagnostic Imaging | 7 | 2013 | 242 | 0.540 |
Why?
|
| Adoptive Transfer | 2 | 2007 | 145 | 0.530 |
Why?
|
| Tissue Distribution | 13 | 2019 | 282 | 0.530 |
Why?
|
| Carrier Proteins | 3 | 2012 | 710 | 0.530 |
Why?
|
| HIV-1 | 2 | 2019 | 707 | 0.530 |
Why?
|
| Microscopy, Fluorescence | 12 | 2019 | 397 | 0.520 |
Why?
|
| Photoacoustic Techniques | 1 | 2015 | 5 | 0.520 |
Why?
|
| Cell Nucleus | 1 | 2019 | 603 | 0.520 |
Why?
|
| Radionuclide Imaging | 13 | 2005 | 116 | 0.510 |
Why?
|
| Adenocarcinoma | 6 | 2005 | 322 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2012 | 180 | 0.510 |
Why?
|
| Phantoms, Imaging | 8 | 2018 | 210 | 0.510 |
Why?
|
| Gliosarcoma | 5 | 2003 | 6 | 0.510 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 8 | 0.510 |
Why?
|
| Immunoglobulin Fab Fragments | 4 | 2021 | 43 | 0.500 |
Why?
|
| Models, Molecular | 4 | 2013 | 1125 | 0.490 |
Why?
|
| Mice, Nude | 13 | 2012 | 259 | 0.480 |
Why?
|
| Genetic Vectors | 7 | 2003 | 813 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 607 | 0.460 |
Why?
|
| Cell Line | 8 | 2020 | 2014 | 0.460 |
Why?
|
| Base Pairing | 2 | 2013 | 36 | 0.460 |
Why?
|
| Oxides | 8 | 2000 | 33 | 0.460 |
Why?
|
| Heterocyclic Compounds | 3 | 2006 | 12 | 0.460 |
Why?
|
| Biomimetics | 1 | 2014 | 28 | 0.450 |
Why?
|
| Gene Transfer Techniques | 5 | 2004 | 304 | 0.450 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 73 | 0.440 |
Why?
|
| Macromolecular Substances | 2 | 2013 | 160 | 0.430 |
Why?
|
| Brain Ischemia | 3 | 2014 | 403 | 0.430 |
Why?
|
| Neuroimaging | 1 | 2014 | 130 | 0.430 |
Why?
|
| Aneurysm, Ruptured | 1 | 2014 | 72 | 0.430 |
Why?
|
| Peroxidases | 2 | 2019 | 7 | 0.420 |
Why?
|
| Electron Spin Resonance Spectroscopy | 3 | 2008 | 24 | 0.410 |
Why?
|
| Coordination Complexes | 1 | 2012 | 8 | 0.410 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 213 | 0.410 |
Why?
|
| Prostatic Neoplasms | 3 | 2006 | 326 | 0.410 |
Why?
|
| Molecular Structure | 8 | 2011 | 375 | 0.410 |
Why?
|
| Annexin A5 | 5 | 2005 | 23 | 0.400 |
Why?
|
| Cell Membrane | 3 | 2003 | 492 | 0.390 |
Why?
|
| Female | 31 | 2020 | 30829 | 0.390 |
Why?
|
| Antineoplastic Agents | 4 | 2005 | 643 | 0.390 |
Why?
|
| Horseradish Peroxidase | 2 | 2011 | 16 | 0.380 |
Why?
|
| Neovascularization, Physiologic | 2 | 2009 | 102 | 0.380 |
Why?
|
| Genetic Engineering | 2 | 2003 | 112 | 0.370 |
Why?
|
| Lung Neoplasms | 2 | 2012 | 547 | 0.370 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 47 | 0.360 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2013 | 39 | 0.350 |
Why?
|
| Inflammation | 4 | 2023 | 1101 | 0.350 |
Why?
|
| Interleukin-1 | 3 | 2006 | 155 | 0.350 |
Why?
|
| Neoplasms, Experimental | 3 | 1999 | 73 | 0.330 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 30 | 0.330 |
Why?
|
| Brain | 3 | 2015 | 1488 | 0.320 |
Why?
|
| Indazoles | 2 | 2005 | 12 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2005 | 15 | 0.320 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 62 | 0.320 |
Why?
|
| Gene Expression | 3 | 2002 | 808 | 0.320 |
Why?
|
| Serotonin | 2 | 2019 | 66 | 0.310 |
Why?
|
| Indium Radioisotopes | 7 | 2007 | 41 | 0.310 |
Why?
|
| Green Fluorescent Proteins | 8 | 2012 | 353 | 0.310 |
Why?
|
| Binding Sites | 7 | 2012 | 875 | 0.310 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 304 | 0.300 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2007 | 17 | 0.300 |
Why?
|
| Water | 5 | 2022 | 295 | 0.300 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 170 | 0.300 |
Why?
|
| Drug Combinations | 3 | 2019 | 140 | 0.290 |
Why?
|
| Plasmids | 3 | 2006 | 282 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2005 | 169 | 0.290 |
Why?
|
| Proteins | 4 | 2008 | 742 | 0.290 |
Why?
|
| Amino Acids | 3 | 2013 | 141 | 0.290 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2019 | 115 | 0.290 |
Why?
|
| Male | 27 | 2020 | 27512 | 0.290 |
Why?
|
| Glucose Oxidase | 1 | 2007 | 5 | 0.290 |
Why?
|
| Cells, Cultured | 9 | 2014 | 2103 | 0.280 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2004 | 4 | 0.280 |
Why?
|
| Blood Volume | 7 | 2012 | 42 | 0.270 |
Why?
|
| Melanins | 3 | 2007 | 19 | 0.260 |
Why?
|
| Polyethyleneimine | 1 | 2006 | 7 | 0.260 |
Why?
|
| Blood Vessels | 3 | 2015 | 61 | 0.260 |
Why?
|
| Gallium Radioisotopes | 1 | 2005 | 11 | 0.260 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2020 | 133 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2005 | 78 | 0.250 |
Why?
|
| Technetium Tc 99m Pentetate | 6 | 1998 | 9 | 0.250 |
Why?
|
| Peptides | 2 | 1999 | 548 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 30 | 0.240 |
Why?
|
| Mice, Inbred DBA | 3 | 2014 | 84 | 0.230 |
Why?
|
| Mutation | 4 | 2019 | 2427 | 0.230 |
Why?
|
| Umbilical Veins | 3 | 2009 | 14 | 0.230 |
Why?
|
| Muscle, Skeletal | 4 | 2022 | 673 | 0.230 |
Why?
|
| Drug Stability | 3 | 2014 | 139 | 0.220 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 213 | 0.220 |
Why?
|
| Apoptosis | 3 | 2003 | 1038 | 0.220 |
Why?
|
| Mammary Neoplasms, Experimental | 4 | 2001 | 62 | 0.220 |
Why?
|
| Rats, Nude | 3 | 2013 | 25 | 0.210 |
Why?
|
| Radiopharmaceuticals | 3 | 2000 | 172 | 0.210 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 695 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2000 | 502 | 0.210 |
Why?
|
| Transplantation, Heterologous | 5 | 2011 | 222 | 0.210 |
Why?
|
| Glycerol | 1 | 2022 | 30 | 0.210 |
Why?
|
| Endopeptidases | 2 | 1999 | 67 | 0.200 |
Why?
|
| Permeability | 2 | 2020 | 47 | 0.200 |
Why?
|
| Isotope Labeling | 3 | 2002 | 68 | 0.200 |
Why?
|
| Viruses | 1 | 2002 | 79 | 0.190 |
Why?
|
| Immunoblotting | 3 | 2012 | 190 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2011 | 569 | 0.190 |
Why?
|
| Reperfusion | 2 | 2018 | 37 | 0.190 |
Why?
|
| Cysteamine | 1 | 2000 | 3 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2012 | 427 | 0.180 |
Why?
|
| Carcinoma, Small Cell | 2 | 1998 | 19 | 0.180 |
Why?
|
| Cerebral Angiography | 2 | 2015 | 278 | 0.180 |
Why?
|
| Stents | 1 | 2024 | 436 | 0.180 |
Why?
|
| Blood-Brain Barrier | 3 | 2012 | 82 | 0.180 |
Why?
|
| Kinetics | 3 | 2012 | 735 | 0.180 |
Why?
|
| Drug Delivery Systems | 3 | 2016 | 307 | 0.180 |
Why?
|
| Rats, Inbred F344 | 7 | 2000 | 51 | 0.180 |
Why?
|
| Prodrugs | 1 | 2000 | 32 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 697 | 0.170 |
Why?
|
| Random Allocation | 1 | 2020 | 198 | 0.170 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 454 | 0.170 |
Why?
|
| Thrombospondin 1 | 1 | 1999 | 6 | 0.170 |
Why?
|
| Ligands | 2 | 2014 | 422 | 0.170 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2014 | 191 | 0.160 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 846 | 0.160 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 3 | 0.160 |
Why?
|
| Benzoxazines | 1 | 2019 | 9 | 0.160 |
Why?
|
| Drug Liberation | 1 | 2019 | 19 | 0.160 |
Why?
|
| Alkynes | 1 | 2019 | 23 | 0.160 |
Why?
|
| COS Cells | 3 | 2006 | 174 | 0.160 |
Why?
|
| Infrared Rays | 1 | 1999 | 16 | 0.160 |
Why?
|
| Cathepsins | 3 | 2012 | 32 | 0.160 |
Why?
|
| Quinolones | 1 | 2019 | 27 | 0.160 |
Why?
|
| Cyclopropanes | 1 | 2019 | 41 | 0.160 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 1998 | 11 | 0.160 |
Why?
|
| Skin | 2 | 2020 | 351 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2014 | 919 | 0.150 |
Why?
|
| Immunotoxins | 1 | 1998 | 7 | 0.150 |
Why?
|
| Cross-Linking Reagents | 4 | 2006 | 112 | 0.150 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 248 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2003 | 525 | 0.150 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 13 | 0.150 |
Why?
|
| Collagen | 3 | 2007 | 121 | 0.150 |
Why?
|
| Encephalitis | 1 | 2018 | 32 | 0.150 |
Why?
|
| Time Factors | 4 | 2014 | 3567 | 0.150 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 154 | 0.140 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 64 | 0.140 |
Why?
|
| Biomarkers | 3 | 2014 | 1205 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 6 | 2012 | 880 | 0.140 |
Why?
|
| Cysteine | 1 | 1997 | 107 | 0.140 |
Why?
|
| Pancreas | 3 | 2011 | 147 | 0.140 |
Why?
|
| Protein Binding | 5 | 2008 | 1550 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2007 | 198 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2004 | 810 | 0.140 |
Why?
|
| Proteoglycans | 2 | 2007 | 33 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2012 | 944 | 0.140 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2016 | 9 | 0.140 |
Why?
|
| Pneumonia | 1 | 2019 | 263 | 0.140 |
Why?
|
| Laminin | 2 | 2007 | 74 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 157 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2017 | 194 | 0.130 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1221 | 0.130 |
Why?
|
| Particle Size | 4 | 2004 | 398 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 1998 | 20 | 0.130 |
Why?
|
| Echoencephalography | 1 | 2015 | 14 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 3190 | 0.130 |
Why?
|
| Cisplatin | 1 | 1996 | 119 | 0.130 |
Why?
|
| Excipients | 2 | 2012 | 49 | 0.120 |
Why?
|
| Gentamicins | 1 | 1995 | 22 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 67 | 0.120 |
Why?
|
| Base Sequence | 2 | 2013 | 1312 | 0.120 |
Why?
|
| Ferrosoferric Oxide | 8 | 2000 | 18 | 0.120 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2014 | 12 | 0.120 |
Why?
|
| Radio Waves | 1 | 2014 | 18 | 0.120 |
Why?
|
| Stroke | 2 | 2018 | 1135 | 0.120 |
Why?
|
| Ablation Techniques | 1 | 2014 | 22 | 0.120 |
Why?
|
| Liver Regeneration | 1 | 2014 | 17 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2000 | 843 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2005 | 183 | 0.120 |
Why?
|
| Macrophages | 3 | 2009 | 1006 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1997 | 484 | 0.120 |
Why?
|
| Motion | 1 | 2014 | 55 | 0.120 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 57 | 0.120 |
Why?
|
| Manganese | 1 | 2014 | 24 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 37 | 0.120 |
Why?
|
| Reperfusion Injury | 1 | 2014 | 51 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2009 | 522 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 1456 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 138 | 0.110 |
Why?
|
| Melanoma | 1 | 1997 | 334 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2016 | 314 | 0.110 |
Why?
|
| Cattle | 1 | 2014 | 306 | 0.110 |
Why?
|
| Endocytosis | 3 | 2005 | 148 | 0.110 |
Why?
|
| Blood Proteins | 2 | 2012 | 72 | 0.110 |
Why?
|
| Thymidine | 2 | 2008 | 25 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 371 | 0.110 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2012 | 23 | 0.110 |
Why?
|
| Mannitol | 1 | 2012 | 14 | 0.100 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2012 | 3 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 505 | 0.100 |
Why?
|
| Cell Extracts | 1 | 2012 | 25 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 50 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 61 | 0.100 |
Why?
|
| Oligonucleotide Probes | 1 | 2012 | 43 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 306 | 0.100 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 75 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 404 | 0.100 |
Why?
|
| Antioxidants | 1 | 2014 | 243 | 0.100 |
Why?
|
| Insulin, Long-Acting | 1 | 2011 | 2 | 0.100 |
Why?
|
| Solubility | 1 | 2012 | 173 | 0.100 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2012 | 90 | 0.100 |
Why?
|
| Wheat Germ Agglutinins | 3 | 1994 | 8 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 3095 | 0.100 |
Why?
|
| Magnetics | 2 | 2006 | 53 | 0.090 |
Why?
|
| Indicators and Reagents | 3 | 2002 | 44 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 439 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 307 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 233 | 0.090 |
Why?
|
| Aged | 2 | 2018 | 13295 | 0.090 |
Why?
|
| Endothelial Growth Factors | 2 | 2001 | 21 | 0.090 |
Why?
|
| Body Water | 2 | 2008 | 16 | 0.090 |
Why?
|
| Lymphokines | 2 | 2001 | 66 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 98 | 0.090 |
Why?
|
| Adult | 3 | 2018 | 15735 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 211 | 0.080 |
Why?
|
| Nitrilotriacetic Acid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Middle Aged | 2 | 2018 | 16238 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 48 | 0.080 |
Why?
|
| Cell Transformation, Viral | 1 | 1989 | 16 | 0.080 |
Why?
|
| Microcirculation | 2 | 2007 | 50 | 0.080 |
Why?
|
| Concanavalin A | 1 | 1989 | 40 | 0.080 |
Why?
|
| Cyclophosphamide | 3 | 2004 | 71 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 220 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2002 | 671 | 0.080 |
Why?
|
| Jurkat Cells | 3 | 2003 | 102 | 0.080 |
Why?
|
| Succinimides | 1 | 1988 | 17 | 0.080 |
Why?
|
| Young Adult | 1 | 2018 | 4321 | 0.080 |
Why?
|
| Cell Transplantation | 2 | 2006 | 39 | 0.080 |
Why?
|
| Spectrum Analysis | 2 | 2005 | 51 | 0.070 |
Why?
|
| Phenol | 1 | 2007 | 2 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2009 | 147 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2008 | 32 | 0.070 |
Why?
|
| Cell Death | 2 | 2007 | 267 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 31 | 0.070 |
Why?
|
| Chromatography | 1 | 2007 | 16 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2008 | 138 | 0.070 |
Why?
|
| Cations | 1 | 2008 | 63 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 1549 | 0.070 |
Why?
|
| Cell Movement | 1 | 2009 | 422 | 0.070 |
Why?
|
| Biochemistry | 1 | 1988 | 50 | 0.070 |
Why?
|
| Adolescent | 1 | 2018 | 5918 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 13 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2002 | 1470 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 168 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 133 | 0.070 |
Why?
|
| Catalysis | 1 | 2007 | 154 | 0.070 |
Why?
|
| Solutions | 1 | 2006 | 62 | 0.070 |
Why?
|
| Temperature | 1 | 2007 | 300 | 0.070 |
Why?
|
| Selectins | 1 | 2006 | 2 | 0.070 |
Why?
|
| Nuclease Protection Assays | 1 | 2006 | 3 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 285 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 74 | 0.070 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 110 | 0.070 |
Why?
|
| Deoxyribonuclease I | 1 | 2006 | 38 | 0.060 |
Why?
|
| Erythrocyte Volume | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 169 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 855 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 219 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 91 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5142 | 0.060 |
Why?
|
| Surface Properties | 2 | 2024 | 270 | 0.060 |
Why?
|
| Dysprosium | 1 | 2005 | 1 | 0.060 |
Why?
|
| Arthritis, Experimental | 1 | 2005 | 29 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 35 | 0.060 |
Why?
|
| Molecular Weight | 2 | 2002 | 187 | 0.060 |
Why?
|
| Tomography, Optical | 1 | 2004 | 3 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2005 | 321 | 0.060 |
Why?
|
| Extracellular Space | 1 | 2004 | 30 | 0.060 |
Why?
|
| Methotrexate | 1 | 2005 | 76 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2024 | 41 | 0.060 |
Why?
|
| Nanostructures | 1 | 2006 | 174 | 0.060 |
Why?
|
| Molecular Conformation | 2 | 2002 | 132 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 219 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2005 | 861 | 0.050 |
Why?
|
| Refractometry | 1 | 2022 | 4 | 0.050 |
Why?
|
| Luciferases | 1 | 2002 | 109 | 0.050 |
Why?
|
| Computer Simulation | 4 | 2012 | 454 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 1999 | 166 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2002 | 55 | 0.050 |
Why?
|
| Cell Division | 2 | 2000 | 442 | 0.050 |
Why?
|
| Photons | 1 | 2002 | 26 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 213 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 140 | 0.050 |
Why?
|
| Suspensions | 2 | 2000 | 9 | 0.050 |
Why?
|
| Microscopy | 1 | 2002 | 88 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 1093 | 0.050 |
Why?
|
| Capillary Permeability | 2 | 1998 | 14 | 0.050 |
Why?
|
| Magnetite Nanoparticles | 2 | 2000 | 28 | 0.050 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2001 | 15 | 0.050 |
Why?
|
| Propanols | 1 | 2000 | 1 | 0.050 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 13 | 0.050 |
Why?
|
| Biotransformation | 1 | 2000 | 20 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 42 | 0.050 |
Why?
|
| Metallothionein | 1 | 2000 | 8 | 0.050 |
Why?
|
| Liver | 5 | 2014 | 785 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 847 | 0.040 |
Why?
|
| Phenols | 1 | 2000 | 74 | 0.040 |
Why?
|
| Neprilysin | 1 | 1999 | 10 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 1999 | 31 | 0.040 |
Why?
|
| Protein Sorting Signals | 1 | 1999 | 57 | 0.040 |
Why?
|
| Hypotension | 1 | 1999 | 47 | 0.040 |
Why?
|
| Mesoporphyrins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Metalloporphyrins | 1 | 1999 | 3 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 1999 | 59 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 1539 | 0.040 |
Why?
|
| Spin Labels | 1 | 1998 | 12 | 0.040 |
Why?
|
| Cell Survival | 2 | 2002 | 553 | 0.040 |
Why?
|
| Kidney | 1 | 2000 | 391 | 0.040 |
Why?
|
| Simplexvirus | 1 | 1998 | 24 | 0.040 |
Why?
|
| Nitrobenzoates | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sepharose | 1 | 1998 | 7 | 0.040 |
Why?
|
| Lysosomes | 1 | 1999 | 162 | 0.040 |
Why?
|
| Organotechnetium Compounds | 1 | 1998 | 28 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 199 | 0.040 |
Why?
|
| Biotinylation | 1 | 1998 | 38 | 0.040 |
Why?
|
| Spermatic Cord | 1 | 1997 | 1 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 1998 | 46 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 1998 | 48 | 0.040 |
Why?
|
| Spermatic Cord Torsion | 1 | 1997 | 11 | 0.040 |
Why?
|
| Virion | 1 | 1998 | 117 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 527 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 385 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 1997 | 98 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2011 | 470 | 0.040 |
Why?
|
| Proton Pumps | 1 | 1996 | 7 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2006 | 201 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 396 | 0.030 |
Why?
|
| Secretin | 1 | 1996 | 6 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 500 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 51 | 0.030 |
Why?
|
| Muscles | 2 | 1993 | 171 | 0.030 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 42 | 0.030 |
Why?
|
| Drug Implants | 1 | 1995 | 17 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 1995 | 31 | 0.030 |
Why?
|
| Imidocarb | 1 | 1994 | 1 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1995 | 87 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2012 | 519 | 0.030 |
Why?
|
| Axonal Transport | 1 | 1994 | 31 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 1994 | 17 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 1582 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1995 | 105 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 1977 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1995 | 86 | 0.030 |
Why?
|
| Colloids | 1 | 1994 | 49 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2014 | 55 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1996 | 379 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1994 | 247 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1994 | 90 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1998 | 685 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 1993 | 174 | 0.030 |
Why?
|
| Asialoglycoproteins | 1 | 1993 | 1 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 1993 | 67 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 1994 | 211 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1993 | 16 | 0.030 |
Why?
|
| Axons | 1 | 1993 | 120 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1993 | 29 | 0.030 |
Why?
|
| Injections, Intravenous | 3 | 1998 | 148 | 0.030 |
Why?
|
| Micelles | 1 | 2012 | 78 | 0.030 |
Why?
|
| Molecular Probe Techniques | 1 | 2012 | 6 | 0.030 |
Why?
|
| Rhodamines | 3 | 2000 | 20 | 0.020 |
Why?
|
| Insulin Glargine | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 20 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2014 | 283 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 30 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1994 | 169 | 0.020 |
Why?
|
| Oxygen | 2 | 2006 | 307 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 34 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1999 | 1129 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2001 | 21 | 0.020 |
Why?
|
| Trypsin | 1 | 1989 | 41 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 97 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 77 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 68 | 0.020 |
Why?
|
| Carbodiimides | 1 | 1988 | 1 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 485 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 145 | 0.020 |
Why?
|
| Plant Lectins | 1 | 2006 | 6 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 39 | 0.020 |
Why?
|
| Response Elements | 1 | 2006 | 42 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 658 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 69 | 0.020 |
Why?
|
| Autoradiography | 2 | 1998 | 53 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 208 | 0.020 |
Why?
|
| P-Selectin | 1 | 2006 | 26 | 0.020 |
Why?
|
| Eye | 1 | 2006 | 54 | 0.020 |
Why?
|
| Leukocytes | 1 | 2006 | 108 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 506 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2006 | 211 | 0.020 |
Why?
|
| Synovial Fluid | 1 | 2005 | 29 | 0.020 |
Why?
|
| Joints | 1 | 2005 | 30 | 0.010 |
Why?
|
| Sciatic Nerve | 2 | 1994 | 22 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 67 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 43 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2003 | 17 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1140 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 645 | 0.010 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 21 | 0.010 |
Why?
|
| Camptothecin | 1 | 2002 | 23 | 0.010 |
Why?
|
| Metals, Rare Earth | 1 | 2001 | 1 | 0.010 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2001 | 6 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 1988 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 17 | 0.010 |
Why?
|
| Cytosine | 1 | 2000 | 30 | 0.010 |
Why?
|
| Bisbenzimidazole | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cathepsin H | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cathepsin B | 1 | 1999 | 12 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2000 | 72 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 90 | 0.010 |
Why?
|
| Echo-Planar Imaging | 1 | 1998 | 32 | 0.010 |
Why?
|
| Half-Life | 1 | 1998 | 70 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 69 | 0.010 |
Why?
|
| DEAE-Dextran | 1 | 1998 | 1 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1998 | 13 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1998 | 20 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1999 | 232 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 121 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 1998 | 41 | 0.010 |
Why?
|
| Blood Volume Determination | 1 | 1997 | 4 | 0.010 |
Why?
|
| Neuroglia | 1 | 1998 | 79 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1998 | 120 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 340 | 0.010 |
Why?
|
| Spleen | 1 | 1998 | 485 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1998 | 257 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 170 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 51 | 0.010 |
Why?
|
| Streptavidin | 1 | 1996 | 32 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 20 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 102 | 0.010 |
Why?
|
| Biotin | 1 | 1996 | 52 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 293 | 0.010 |
Why?
|
| Thigh | 1 | 1995 | 25 | 0.010 |
Why?
|
| Models, Structural | 1 | 1995 | 25 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 107 | 0.010 |
Why?
|
| Femoral Nerve | 1 | 1994 | 5 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1994 | 14 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1994 | 12 | 0.010 |
Why?
|
| Babesiosis | 1 | 1994 | 10 | 0.010 |
Why?
|
| Platelet Count | 1 | 1994 | 33 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1994 | 35 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 298 | 0.010 |
Why?
|
| Horse Diseases | 1 | 1994 | 19 | 0.010 |
Why?
|
| Horses | 1 | 1994 | 49 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 183 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 663 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 166 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1993 | 11 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1994 | 70 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1994 | 85 | 0.010 |
Why?
|
| Superior Colliculi | 1 | 1993 | 12 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 451 | 0.010 |
Why?
|
| Retinal Ganglion Cells | 1 | 1993 | 26 | 0.010 |
Why?
|
| Gels | 1 | 1993 | 59 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 99 | 0.010 |
Why?
|
| Cholesterol | 1 | 1994 | 255 | 0.010 |
Why?
|
| Fetuins | 1 | 1993 | 1 | 0.010 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 1993 | 3 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 287 | 0.010 |
Why?
|
| Neurons | 1 | 1998 | 858 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1992 | 6 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1993 | 178 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1996 | 749 | 0.010 |
Why?
|